Anat Erdreich-Epstein
Affiliations: | Neuroscience | University of Southern California, Los Angeles, CA, United States |
Area:
OncologyGoogle:
"Anat Erdreich-Epstein"Mean distance: 53433
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nemes K, Benesch M, Kolarova J, et al. (2023) Rhabdoid tumors in patients conceived following ART: is there an association? Human Reproduction (Oxford, England) |
| Elghetany MT, Ho JM, Shi-Qi LH, et al. (2021) Maximizing the potential of aggressive mouse tumor models in preclinical drug testing. Scientific Reports. 11: 11580 |
| Xue Y, Zhu X, Meehan B, et al. (2020) SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors. The Journal of Pathology |
| Gujar H, Zhang L, Li H, et al. (2020) Abstract 462: The mutated chromatin modifier gene, H3F3AK27M, is a druggable target of DNA hypomethylating agents in pediatric high-grade glioma Cancer Research. 80: 462-462 |
| Pathania AS, Ren X, Mahdi MY, et al. (2019) GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis. Scientific Reports. 9: 13902 |
| Shackleford GM, Mahdi MY, Moats RA, et al. (2019) Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma. Plos One. 14: e0206394 |
| Pathania AS, Ren X, Mahdi M, et al. (2019) Abstract 2053: Targeting GRK2 increases chemotherapy-induced apoptosis in medulloblastoma Cancer Research. 79: 2053-2053 |
| Ren X, Hirsh E, Mahdi M, et al. (2019) CSIG-29. STRUCTURAL AND FUNCTIONAL STUDIES OF PID1, A NOVEL GROWTH SUPPRESSOR IN BRAIN TUMORS Neuro-Oncology. 21: vi50-vi50 |
| Ho J, Karthik S, M.F. Su J, et al. (2019) ATRT-06. ISPINESIB IS AN EFFICACIOUS THERAPEUTIC AGENT FOR ATYPICAL TERATOID RHABDOID TUMORS Neuro-Oncology. 21: ii64-ii64 |
| Erdreich-Epstein A, Singh AR, Joshi S, et al. (2017) Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 8: 52193-52210 |